Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

lysosomal degradation pathway

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Amyloid-β (1) Apoptosis (5) ATTECs (1) Autophagy (8) CCR (1) CDK (1) Deubiquitinase (1) EGFR (1) Epoxide Hydrolase (1) LYTACs (2) Mitochondrial Metabolism (1) Mitosis (3) Monoamine Oxidase (3) mTOR (1) NAMPT (1) PD-1/PD-L1 (1) Prion Protein (1) PROTACs (3) Ras (1) Reference Standards (1) Tau Protein (1) YAP (1) α-synuclein (3)
By Research Areas:	Cancer (14) Cardiovascular Disease (1) Endocrinology (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (6)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Targets Recommended: Tissue Factor Pathway Inhibitor (TFPI)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13817

IU1 Maximum Cited Publications 25 Publications Verification	Deubiquitinase Autophagy Apoptosis	Cardiovascular Disease Neurological Disease Endocrinology Cancer
IU1 is a selective, reversible USP14 inhibitor with an IC₅₀ of 4-5 μM. IU1 binds USP14’s catalytic cleft to block deubiquitinase activity. IU1 induces calpain-dependent Tau cleavage, causes ATP deficits, reduces E1~Ub thioester levels and 26S proteasome assembly. IU1 enhances 26S proteasome chymotrypsin-like activity, modulates LC3B-dependent autophagy flux, reduces cancer cell proliferation and migration, and blocks G0/G1 to S phase cell cycle transition in follicular thyroid cancer cells. IU1 activates autophagy-lysosomal and ubiquitin-proteasome pathways, triggers apoptosis, and reduces cervical cancer cell growth. IU1 enhances degradation of proteasome substrates linked to neurodegenerative disease, accelerates oxidized protein degradation, and increases oxidative stress resistance. IU1 can be used for the research of Alzheimer’s disease, follicular thyroid cancer, ischemic stroke, cervical cancer, and neurodegenerative disease .

HY-155747

FDW028 1 Publications Verification	Autophagy Akt mTOR	Cancer
FDW028 a potent and highly selective FUT8 inhibitor. FUT8 exhibits potent anti-tumor activity by defucosylation and impelling lysosomal degradation of B7-H3 through the chaperone-mediated autophagy (CMA) pathway. FDW028 can be used for metastatic colorectal cancer (mCRC) research .

HY-107811

Harmol 1 Publications Verification	Autophagy α-synuclein Apoptosis Monoamine Oxidase Mitosis	Neurological Disease Cancer
Harmol is an orally active β-carboline alkaloid. Harmol is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of α-synuclein by regulating the *autophagy-lysosomal* pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

HY-148118A

Tri-GalNAc(OAc)3 TFA	LYTACs	Cancer
Tri-GalNAc(OAc)3 TFA is a trivalent N-acetylgalactosamine (GalNAc) derivative that can be used to synthesize GalNAc-LYTAC. Tri-GalNAc is a specific ligand targeting the asialoglycoprotein receptor (ASGPR), mediating the endocytosis and transport of cell surface proteins (such as EGFR, HER2) to lysosomes for degradation by lysosomal targeting chimeras (LYTACs). Tri-GalNAc significantly reduces the level of target proteins and inhibits downstream signaling pathways (such as EGFR-mediated Akt and MAPK signals). Tri-GalNAc(OAc)3 TFA can be used for hepatocyte targeting studies, and can degrade carcinogenic membrane proteins and inhibit tumor cell proliferation in liver cancer cell models .

HY-125168

EGA 2 Publications Verification	EGFR	Infection Inflammation/Immunology
EGA is an inhibitor that selectively targets the endosomal trafficking pathways. EGA targets the proteins involved in the endosomal trafficking pathways through which multiple toxins and viruses enter cells. EGA exerts its activity by inhibiting the trafficking from early endosomes to late endosomes, blocking the entry of multiple acid-dependent bacterial toxins and viruses into mammalian cells and delaying the lysosomal targeting and degradation of EGFR .

HY-153880

KRAS degrader-1	LYTACs Ras	Cancer
KRAS degrader-1 is a potent KRAS degrader. KRAS degrader-1 targets specific proteins for degradation via the autophagy-lysosomal degradation pathway. KRAS degrader-1 is suitable for use in cancer research. (Blue: KRAS G12C-IN-72 (HY-128414); Black: Linker (HY-175587); Pink: 5-Iodoindolin-2-one (HY-76986); Blue + Black: KRAS ligand-Linker Conjugate 7 (HY-175586)) .

HY-150286

SM875	Prion Protein	Neurological Disease
SM875 is a cellular prion protein (PrP) degrader (IC₅₀: 7.87 μM). SM875 targets PrP folding intermediates and promotes its degradation through the autophagy-lysosomal pathway. SM875 only acts on nascent, immature PrP molecules and has no effect on mature PrP before synthesis. SM875 can inhibit prion replication and has potential in the study of neurodegenerative diseases (i.e., prion diseases) .

HY-147656

NAMPT degrader-1	ATTECs NAMPT Autophagy	Cancer
NAMPT degrader-1 (Compound A3), an autophagosome-tethering compound (ATTEC), is an nicotinamide phosphoribosyltransferase (NAMPT) degrader with an IC₅₀ of 0.023 μM. NAMPT degrader-1 significantly induces the degradation of NAMPT through the *autophagy*-lysosomal pathway and shows excellent cellular antitumor potency .

HY-162972

PROTAC PD-L1 degrader-2	PROTACs PD-1/PD-L1	Inflammation/Immunology Cancer
PROTAC PD-L1 degrader-2 is a PD-L1 PROTAC degrader with an IC₅₀ of 197.4 nM and a K_d of 301 nM. PROTAC PD-L1 degrader-2 induces PD-L1 endocytosis, drives degradation via the proteasomal and lysosomal pathways, and inhibits the PD-1/PD-L1 interaction. As an immune activator, PROTAC PD-L1 degrader-2 increases the levels of CD4 ⁺, CD8 ⁺, granzyme B and perforin. PROTAC PD-L1 degrader-2 can be used in studies related to colon cancer immunology .

HY-107811A

Harmol hydrochloride	Autophagy α-synuclein Apoptosis Monoamine Oxidase Mitosis	Neurological Disease Cancer
Harmol hydrochloride is an orally active β-carboline alkaloid. Harmol hydrochloride is a TFEB activator and monoamine oxidase inhibitor. Harmol hydrochloride can induce cell mitosis, Autophagy and Apoptosis. Harmol hydrochloride promotes the degradation of α-synuclein by regulating the *autophagy-lysosomal* pathway. Harmol hydrochloride has anti-tumor, anti-depressant and anti-aging activities. Harmol hydrochloride improves motor impairment in a mouse Parkinson's disease model .

HY-175392

PROTAC sEH-degrader-3	PROTACs Epoxide Hydrolase	Metabolic Disease Inflammation/Immunology
PROTAC sEH-degrader-3 (Compound 1a) is a targeted sEH PROTAC degrader that can selectively degrade sEH in the cytosol without affecting sEH in peroxisomes. PROTAC sEH-degrader-3 degrades sEH through a CRBN-dependent lysosomal pathway rather than the proteasome, with an IC₅₀ of 0.8 nM against hsEH. PROTAC sEH-degrader-3 can inhibit endoplasmic reticulum stress and can be used in the research of inflammation, metabolic diseases, and other diseases related to endoplasmic reticulum stress. (Pink: sEH inhibitor (HY-114266); Black: Linker (HY-W008352); Blue: E3 Ligase Ligand (HY-14658)) .

HY-173150

Hapalindole Q	YAP	Cancer
Hapalindole Q (Compound (+)-1) is an autophagy (Autophagy) inhibitor targeting YAP1. Hapalindole Q binds to the Hippo pathway transcription factor YAP1 with a K_d of 9.13 μM and induces its degradation via the chaperone-mediated autophagy (CMA) pathway. This process inhibits Rab7-mediated fusion of autophagosomes and lysosomes, thereby reducing overall autophagy levels without affecting lysosomal function. Hapalindole Q holds promise for research in cancer (e.g., liver cancer, breast cancer, etc.) .

HY-203817

IITZ-02	Autophagy Apoptosis Mitochondrial Metabolism	Cancer
IITZ-02 is a lysosomotropic Autophagy inhibitor. IITZ-02 enhances autophagosome accumulation but inhibits autophagosomal degradation by impairing lysosomal function, finally inducing the inhibition of autophagy. IITZ-02 abolishes mitochondrial membrane potential and induces apoptosis through the mitochondria-mediated pathway. IITZ-02 has a potent antitumor activity in MDA-MB-231 xenograft mouse models. IITZ-02 can be used for cancers research .

HY-107811R

Harmol (Standard)	Apoptosis Monoamine Oxidase Autophagy α-synuclein Mitosis Reference Standards	Neurological Disease Cancer
Harmol (Standard) is the analytical standard of Harmol (HY-107811). This product is intended for research and analytical applications. Harmol hydrochloride is an orally active β-carboline alkaloid. Harmol hydrochloride is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of α-synuclein by regulating the *autophagy-lysosomal* pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

HY-180571

LUF7996	PROTACs CCR	Cancer
LUF7996 is a CCR2 PROTAC Degrader degrading CCR2 with DC₅₀ = 2.6 μM. LUF7996 demonstrates engagement of both and the E3 ligase cereblon and displays sustain and concentration-dependent degradation of CCR2. LUF7996 reliance on the lysosomal pathway to induce CCR2 degradation. LUF7996 efficiently inhibits monocyte migration in virto .

HY-183660

F-SLOH	Autophagy Amyloid-β Tau Protein	Neurological Disease
F-SLOH is a brain-penerant and orally active TFEB activator and amyloid-β inhibitor with an IC₅₀ of 3.4 μM against amyloid-β. F-SLOH promotes nuclear translocation of TFEB, driving autophagy and lysosomal biogenesis. F-SLOH reduces amyloid-β oligomers and Tau aggregates via autophagy lysosomal degradation pathway. F-SLOH can be used for the research of Alzheimer’s disease .

HY-180222

KGA-4066	CDK	Cancer
KGA-4066 is a novel non-ATP-competitive CDK2 inhibitor. KGA-4066 inhibits CDK2/Cyclin A2 with an IC₅₀ value of 236.7 nM, disrupts their interaction, promots CDK2 degradation via the lysosomal pathway. KGA-4066 has anticancer activity against hepatocellular carcinoma .

HY-183717

M4K3233		Cancer
M4K3233 is a selective ALK2 PROTAC degrader with a pDC₅₀ of 7.3 and a pIC₅₀ of 6.6. M4K3233 recruits CRBN to form a ternary complex with ALK2, mediating ALK2 degradation via the proteasomal and lysosomal pathways. M4K3233 induces moderate downregulation of RIPK2 and significant downregulation of SIK3 in mammalian cells. M4K3233 is applicable to research related to glioblastoma .

Cat. No.	Product Name

HY-L029

Autophagy Compound Library	1,996 compounds
Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, and homeostasis. The process of autophagy in mammalian cells is as follows: a portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses with the endosome and then the lysosome, and the internal material is degraded. Autophagy plays a wide variety of physiological and pathophysiological roles. Defective autophagy contributes to various pathologies, including infections, cancer, neurodegeneration, aging, and heart disease. MCE provides a unique collection of 1,996 autophagy pathway-related compounds that is a useful tool for the research of autophagy-related regulation and diseases.

Autophagy Compound Library

1,996 compounds

Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, and homeostasis. The process of autophagy in mammalian cells is as follows: a portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses with the endosome and then the lysosome, and the internal material is degraded. Autophagy plays a wide variety of physiological and pathophysiological roles. Defective autophagy contributes to various pathologies, including infections, cancer, neurodegeneration, aging, and heart disease.

MCE provides a unique collection of 1,996 autophagy pathway-related compounds that is a useful tool for the research of autophagy-related regulation and diseases.

Harmol 1 Publications Verification	Neurological Disease Classification of Application Fields Peganum harmala Linn. Pyridine Alkaloids Plants Endogenous metabolite Indole Alkaloids Alkaloids Monophenols Zygophyllaceae Phenols Disease Research Fields Source Classification	Autophagy α-synuclein Apoptosis Monoamine Oxidase Mitosis
Harmol is an orally active β-carboline alkaloid. Harmol is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of α-synuclein by regulating the *autophagy-lysosomal* pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

Hapalindole Q	Structural Classification Alkaloids Microorganisms Other Alkaloids Source Classification	YAP
Hapalindole Q (Compound (+)-1) is an autophagy (Autophagy) inhibitor targeting YAP1. Hapalindole Q binds to the Hippo pathway transcription factor YAP1 with a K_d of 9.13 μM and induces its degradation via the chaperone-mediated autophagy (CMA) pathway. This process inhibits Rab7-mediated fusion of autophagosomes and lysosomes, thereby reducing overall autophagy levels without affecting lysosomal function. Hapalindole Q holds promise for research in cancer (e.g., liver cancer, breast cancer, etc.) .

Harmol (Standard)	Alkaloids Monophenols Zygophyllaceae Peganum harmala Linn. Phenols Pyridine Alkaloids Plants Endogenous metabolite Indole Alkaloids Source Classification	Apoptosis Monoamine Oxidase Autophagy α-synuclein Mitosis Reference Standards
Harmol (Standard) is the analytical standard of Harmol (HY-107811). This product is intended for research and analytical applications. Harmol hydrochloride is an orally active β-carboline alkaloid. Harmol hydrochloride is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of α-synuclein by regulating the *autophagy-lysosomal* pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks